ProQR amendment leaves prior disclosures unchanged

Available on EDGAR 10/30/2026 - 04:01 PM EDT Accepted by SEC EDGAR 10/30/2026 - 04:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ProQR Therapeutics N.V. amended prior Form 6-K reports solely to incorporate their information and accompanying exhibits by reference into five Form F-3 registration statements, including related prospectuses, to the extent the material is not superseded by later documents or reports. The amendment does not update or restate the earlier disclosures or reflect events occurring after their original filing dates.

Key Terms

incorporated by reference, Form F-3, prospectuses

3 terms

incorporated by reference regulatory

"hereby incorporated by reference into the Company’s registration statements"

Form F-3 regulatory

"registration statements on Form F-3"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

prospectuses regulatory

"including any prospectuses forming a part of such registration statements"

A prospectus is a formal document that outlines the details of a securities offering—like a brochure for shares or bonds—covering the business, management, financial results, risks, how the raised money will be used, and the exact terms of the sale. Investors use it to compare offerings and judge whether the investment fits their goals and risk tolerance; it’s the primary source for factual information and disclosures before deciding to buy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K/A

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of October, 2026

Commission File Number: 001-36622

PROQR THERAPEUTICS N.V.

Zernikedreef 9

2333 CK Leiden

The Netherlands

Tel: +31 88 166 7000

(Address, Including Zip Code, and Telephone Number,
Including Area Code, of Registrant’s Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

EXPLANATORY NOTE

This Report on Form 6-K/A (the “Amendment”) of ProQR Therapeutics N.V. (the “Company”) amends the Company’s reports on Form 6-K filed with the U.S. Securities and Exchange Commission on August 13, 2026, August 13, 2026, September 9, 2026 and September 23, 2026 (each an “Original Form 6-K”, and as amended the “Form 6-Ks”), solely to incorporate by reference the information contained in each Original Form 6-K, including the exhibits furnished therewith, into the Company’s registration statements on Form F-3 as set forth below.

Except as described above, this Amendment speaks as of the original respective filing date of each Original Form 6-K and does not amend, update or restate any information set forth in any Original Form 6-K or reflect any events that occurred subsequent to the original filing date of any Original Form 6-K.

INCORPORATION BY REFERENCE

The information included in the Form 6-Ks, including the exhibits furnished therewith, is hereby incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-282419, File No. 333-270943, File No. 333-263166, File No. 333-285767 and File No. 333-297272) (including any prospectuses forming a part of such registration statements) and to be a part thereof, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PROQR THERAPEUTICS N.V.
Date: October 30, 2026	By:	/s/ Dennis Hom
		Dennis Hom
		Chief Financial Officer